View more in
Cancer

Consistent Benefit Found with Nivolumab/Ipilimumab Plus Chemotherapy for Advanced NSCLC, According to Updated CheckMate 9LA Study

targetedonc.com
 2021-06-04

Cover picture for the articleContinued efficacy is seen with nivolumab and ipilimumab plus 2 cycles of versus chemotherapy alone for patients with advanced non–small cell lung cancer. Continued efficacy is seen with nivolumab (Opdivo) and ipilimumab (Yervoy) plus 2 cycles of versus chemotherapy alone for patients with advanced non–small cell lung cancer (NSCLC), according to a 2-year follow-up analysis of the CheckMate 9LA trial (NCT03215706) presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.1.

www.targetedonc.com

Comments / 0

Comments / 0